A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
暂无分享,去创建一个
N. Saijo | Y. Nishiwaki | T. Tamura | K. Nakagawa | T. Tamura | T. Shibata | H. Kunitoh | N. Katakami | K. Noda | A. Yokoyama | K. Nakagawa | K. Noda | K. Watanabe | K. Takeda | K. Watanabe
[1] N. Saijo,et al. A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605) , 2009, British Journal of Cancer.
[2] C. Tzen,et al. Debulking surgery for advanced thymoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[3] C. Angeletti,et al. Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] K. Mori,et al. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone , 2005, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] J. Wain,et al. Adjuvant radiation of stage III thymoma: is it necessary? , 2005, The Annals of thoracic surgery.
[6] G. Giaccone. Treatment of malignant thymoma , 2005, Current opinion in oncology.
[7] Charles R. Thomas,et al. Thymic carcinoma: state of the art review. , 2004, International journal of radiation oncology, biology, physics.
[8] Edward S. Kim,et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. , 2004, Lung cancer.
[9] H. Müller-Hermelink,et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] H. Onishi,et al. Postoperative radiotherapy for patients with completely resected thymoma , 2002, Cancer.
[11] Charles R. Thomas,et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma , 2001, Cancer.
[12] M. Brizzi,et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience , 1999, British Journal of Cancer.
[13] N. Saijo,et al. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Chen,et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Dromer,et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. , 1996, The Journal of thoracic and cardiovascular surgery.
[16] G. Giaccone,et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] I. Ciernik,et al. Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Livingston,et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Y. Shimada,et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. , 1993, Japanese journal of clinical oncology.
[20] D. Osoba,et al. Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Urgesi,et al. Role of radiation therapy in locally advanced thymoma. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] W. Curran,et al. Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Murray. The importance of dose and dose intensity in lung cancer chemotherapy. , 1987, Seminars in oncology.
[24] W. Hryniuk,et al. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Goldie Jh,et al. Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .
[26] Y. Monden,et al. Follow‐up study of thymomas with special reference to their clinical stages , 1981, Cancer.
[27] N. Girard,et al. Thymoma: a focus on current therapeutic management. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] M. Fukuoka,et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. , 1997, British Journal of Cancer.
[29] J. Goldie,et al. Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.
[30] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.